Advertisement
UK markets open in 59 minutes

  • NIKKEI 225

    37,245.41
    -834.29 (-2.19%)
     

  • HANG SENG

    16,154.82
    -231.05 (-1.41%)
     

  • CRUDE OIL

    84.24
    +1.51 (+1.83%)
     

  • GOLD FUTURES

    2,396.90
    -1.10 (-0.05%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • Bitcoin GBP

    50,033.62
    +828.39 (+1.68%)
     

  • CMC Crypto 200

    1,284.14
    -28.49 (-2.13%)
     

  • NASDAQ Composite

    15,601.50
    -81.87 (-0.52%)
     

  • UK FTSE All Share

    4,290.02
    +17.00 (+0.40%)
     
Money:

Best mortgage deals of the week

As possibility of multiple interest rate cuts dwindle here's what banks and building societies are offering

AstraZeneca, Merck cancer treatment attains meaningful improvement in progression-free survival

Reuters - UK Focus

Sept 30 (Reuters) - AstraZeneca Plc and Merck & Co Inc said on Monday their drug to treat a form of ovarian cancer improved progression-free survival in patients tested in a late-stage study.

The study tested Lynparza in patients as an add-on to an already existing standard of care, bevacizumab, and was compared to a group of patients given bevacizumab alone.

Lynparza added to bevacizumab reduced the risk of disease progression or death by 41% in the overall trial population. (Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Bernard Orr)